These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

55 related items for PubMed ID: 1389660

  • 1. Pharmacokinetics of iopentol in patients with chronic renal failure.
    Svaland MG, Kolmannskog F, Lillevold PE, Nordal KP, Ressem L, Berg KJ.
    Acta Radiol; 1992 Sep; 33(5):482-4. PubMed ID: 1389660
    [Abstract] [Full Text] [Related]

  • 2. Iopentol in patients with chronic renal failure: its effects on renal function and its use as glomerular filtration rate parameter.
    Berg KJ, Kolmannskog F, Lillevold PE, Nordal KP, Ressem L, Rootwelt K, Svaland MG.
    Scand J Clin Lab Invest; 1992 Feb; 52(1):27-33. PubMed ID: 1594886
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics of buflomedil after intravenous administration in patients with chronic renal failure.
    Rey E, d'Athis P, Richard MO, Fillastre JP, Olive G.
    Int J Clin Pharmacol Ther Toxicol; 1984 Dec; 22(12):648-52. PubMed ID: 6526539
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics of iopentol in the rat.
    Michelet AA, Skinnemoen K.
    Acta Radiol Suppl; 1987 Dec; 370():101-4. PubMed ID: 2980301
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics of iotrolan after intravenous injection into healthy volunteers.
    Scholz P, Weinmann HJ, Mützel W, Staks T.
    Fortschr Geb Rontgenstrahlen Nuklearmed Erganzungsbd; 1989 Dec; 128():211-4. PubMed ID: 2568798
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics of iopentol in healthy volunteers.
    Waaler A, Jørgensen NP, Koksvik B, Skinnemoen K, Andrew E.
    Acta Radiol Suppl; 1987 Dec; 370():113-7. PubMed ID: 2980304
    [Abstract] [Full Text] [Related]

  • 7. Renal effects of iopentol and iohexol after intravenous injection.
    Jakobsen JA, Kolbenstvedt AN, Berg KJ.
    Acta Radiol; 1991 Jul; 32(4):320-4. PubMed ID: 1863505
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics of nicotine in kidney failure.
    Molander L, Hansson A, Lunell E, Alainentalo L, Hoffmann M, Larsson R.
    Clin Pharmacol Ther; 2000 Sep; 68(3):250-60. PubMed ID: 11014406
    [Abstract] [Full Text] [Related]

  • 9. The elimination of tritiated doxycycline in normal subjects and in patients with severely impaired renal function.
    Mahon WA, Johnson GE, Endrenyl L, Kelly MF, Fenton SS.
    Scand J Infect Dis Suppl; 1976 Sep; (9):24-31. PubMed ID: 1070145
    [Abstract] [Full Text] [Related]

  • 10. Renal effects of the non-ionic contrast medium iopentol after intravenous injection in healthy volunteers.
    Jakobsen JA, Berg KJ, Waaler A, Andrew E.
    Acta Radiol; 1990 Jan; 31(1):87-91. PubMed ID: 2187515
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics of oral cefatrizine in patients with impaired renal function.
    Couet W, Fauvel JP, Laville M, Pozet N, Fourtillan JB.
    Int J Clin Pharmacol Ther Toxicol; 1991 Jun; 29(6):213-7. PubMed ID: 1869342
    [Abstract] [Full Text] [Related]

  • 12. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
    De Martin S, Orlando R, Bertoli M, Pegoraro P, Palatini P.
    Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
    [Abstract] [Full Text] [Related]

  • 13. Effect of haemodialysis after contrast medium administration in patients with renal insufficiency.
    Lehnert T, Keller E, Gondolf K, Schäffner T, Pavenstädt H, Schollmeyer P.
    Nephrol Dial Transplant; 1998 Feb; 13(2):358-62. PubMed ID: 9509446
    [Abstract] [Full Text] [Related]

  • 14. [Pharmacokinetics of zidovudine (AZT) and its metabolite (G-AZT) in healthy subjects and in patients with kidney failure].
    Pioger JC, Taburet AM, Colin JN, Colaneri S, Fillastre JP, Singlas E.
    Therapie; 1989 Feb; 44(6):401-4. PubMed ID: 2623653
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics of iopamidol in adults with renal failure.
    Corradi A, Menta R, Cambi V, Maccarini P, Cerutti R.
    Arzneimittelforschung; 1990 Jul; 40(7):830-2. PubMed ID: 2222559
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics of cefotaxime after a single intravenous dose in patients with impaired renal function.
    Moukhtar I, Nawishy S, Sabbour M.
    Chemioterapia; 1987 Feb; 6(1):38-40. PubMed ID: 3829135
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics of alpha-lipoic acid in subjects with severe kidney damage and end-stage renal disease.
    Teichert J, Tuemmers T, Achenbach H, Preiss C, Hermann R, Ruus P, Preiss R.
    J Clin Pharmacol; 2005 Mar; 45(3):313-28. PubMed ID: 15703366
    [Abstract] [Full Text] [Related]

  • 18. Metabolic clearance of recombinant human growth hormone in health and chronic renal failure.
    Haffner D, Schaefer F, Girard J, Ritz E, Mehls O.
    J Clin Invest; 1994 Mar; 93(3):1163-71. PubMed ID: 8132756
    [Abstract] [Full Text] [Related]

  • 19. Clinical pharmacokinetics of digoxin in Nigerians.
    Iyun AO, Lukanbi FA.
    Afr J Med Med Sci; 1988 Mar; 17(1):9-15. PubMed ID: 2834936
    [Abstract] [Full Text] [Related]

  • 20. Elimination of ioversol by hemodialysis.
    Ueda J, Furukawa T, Takahashi S, Sakaguchi K.
    Acta Radiol; 1996 Sep; 37(5):826-9. PubMed ID: 8915301
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.